Lantheus Holdings, Inc. reported third‑quarter 2025 earnings that ended September 30, 2025, with total revenue of $384 million—$20 million above the $364 million consensus estimate—and an adjusted earnings per share of $1.27, narrowly missing the $1.28 estimate by $0.01. The revenue increase of 1.4 % year‑over‑year reflects modest growth in the company’s core radiopharmaceutical and precision‑diagnostics segments, while the slight EPS miss signals pressure on profitability despite the top‑line gain.
Revenue growth was driven by a 6.3 % rise in sales of DEFINITY, offsetting a 7.4 % decline in PYLARIFY sales. The decline in PYLARIFY was largely due to pricing pressure in the Alzheimer’s diagnostic market, whereas the DEFINITY uptick was supported by stronger demand for its oncology imaging agent. Segment‑level performance highlights the company’s ability to maintain growth in high‑margin oncology products while facing competitive pricing in the diagnostic space.
Gross profit margin contracted to 63.5 %, a decline of 471 basis points from the prior year, driven by unfavorable pricing impacts, the inclusion of Evergreen and Life Molecular Imaging (LMI) margin profiles, and increased errors‑and‑omissions (E&O) charges. The margin squeeze indicates that while revenue is growing, the company is experiencing cost and pricing headwinds that are eroding profitability.
Management guided for full‑year 2025 revenue of $1.49 billion to $1.51 billion and adjusted earnings per share of $5.50 to $5.65, a range that remains unchanged from the previous guidance. The steady outlook signals confidence in continued demand for the company’s product portfolio and the expected benefits of the July 2025 acquisition of Life Molecular Imaging, which is expected to expand Lantheus’s near‑ and long‑term growth profile.
CEO Brian Markison emphasized the competitive advantage of the MK‑6240 imaging agent and reiterated the company’s focus on strategic investments in high‑return verticals. CFO Bob Marshall highlighted market dynamics, noting that pricing pressures in the diagnostic segment are being offset by growth in oncology. The company also announced the repurchase of $100 million of common stock in Q3 2025, the planned retirement of CEO Markison effective December 31, 2025, and the appointment of former CEO Mary Anne Heino as Executive Chairperson.
Investors reacted positively to the revenue beat and the firm’s forward‑looking guidance, reflecting confidence in Lantheus’s growth trajectory and the expected benefits of its recent acquisition and product pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.